Skip to content
6-K

Foreign Interim / Material

NYMOX PHARMACEUTICAL CORPORATION NYMXF

0001640334-25-000006

← back to feed
Filed
Jan 2, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$1.88M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$3.16M
Stockholders Equity Q3 2024 · Sep 30, 2024 −$6.3M
Stockholders Equity Q3 2024 · Dec 31, 2023 −$3.17M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$1.9M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$482K
Current Liabilities Q3 2024 · Sep 30, 2024 $6.92M
Current Liabilities Q3 2024 · Dec 31, 2023 $3.8M
Total Liabilities Q3 2024 · Sep 30, 2024 $6.92M
Total Liabilities Q3 2024 · Dec 31, 2023 $3.8M
Current Assets Q3 2024 · Sep 30, 2024 $623K
Current Assets Q3 2024 · Dec 31, 2023 $625K
Total Assets Q3 2024 · Sep 30, 2024 $624K
Total Assets Q3 2024 · Dec 31, 2023 $627K
Rd Expense Q3 2024 · Sep 30, 2024 $511K
Rd Expense Q3 2024 · Sep 30, 2024 $2.66M
Rd Expense Q3 2024 · Sep 30, 2023 $661K
Rd Expense Q3 2024 · Sep 30, 2023 $1.97M
Net Income Q3 2024 · Sep 30, 2024 −$3.64M
Net Income Q3 2024 · Sep 30, 2023 −$3.53M
Cost Of Revenue Q3 2024 · Sep 30, 2024 $0
Cost Of Revenue Q3 2024 · Sep 30, 2024 $0
Cost Of Revenue Q3 2024 · Sep 30, 2023 $0
Cost Of Revenue Q3 2024 · Sep 30, 2023 $0
Revenue Q3 2024 · Sep 30, 2024 $0
Revenue Q3 2024 · Sep 30, 2024 $0
Revenue Q3 2024 · Sep 30, 2023 $0
Revenue restated Q3 2024 · Sep 30, 2023 $5K